A hard-charging group of Novartis execs have been pouring over the late-stage data they gathered to support their successful campaign to win an FDA approval for Mayzent (siponimod) as a landmark new therapy for multiple sclerosis. And it’s paid off.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,